Biomm, a distribution partner of Cytodyn, is set to seek authorisation from the Brazilian National Health Surveillance Agency (ANVISA) to conduct two Phase III clinical trials of leronlimab (PRO 140) in Covid-19 patients.

Marketed as Vyrologix, leronlimab is an investigational humanised immunoglobulin G4 monoclonal antibody that hinders C-C chemokine receptor type 5 (CCR5).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CCR5 is a cellular receptor vital in HIV infection, tumour metastases, nonalcoholic steatohepatitis, as well as other conditions.

Once ANVISA approval is obtained, the Phase III trials will be carried out by a Brazilian academic research organisation, Albert Einstein Israelite Hospital (AEIH).

CytoDyn signed an agreement to collaborate with AEIH earlier this month to conduct these trials.

These Phase III trials for severe and critically ill Covid-19 patients will offer the necessary data required by ANVISA to make leronlimab available for this indication in the country.

CytoDyn noted that these trials will be carried out at up to 45 clinical centres, enrolling 306 critically ill subjects and 594 severely ill subjects. An interim analysis will be performed after enrolling approximately 40% of subjects in each study.

CytoDyn president and CEO Nader Pourhassan said: “We look forward to continuing to identify partnerships in other countries experiencing a surge in Covid-19 cases similar to Brazil, the Philippines and India where leronlimab could potentially save lives.

“We will update investors on the next investment community call on the design of these trials based on the wealth of information we have learned from our previous Covid-19 trials.”

In April this year, CytoDyn and Biomm signed an exclusive supply and distribution agreement that will enable the latter to leronlimab in Brazil on receiving regulatory approval.

Leronlimab has so far been evaluated in 11 clinical trials in nearly 1,200 individuals. It also met primary goals in a Phase III trial, when administered along with standard antiretroviral therapies in HIV patients who were treatment-experienced.